Drew Deniger - 15 Mar 2023 Form 4 Insider Report for Alaunos Therapeutics, Inc. (TCRT)

Role
Vice President, Research and Development
Signature
/s/ Melinda Lackey, Attorney-in-Fact
Issuer symbol
TCRT
Transactions as of
15 Mar 2023
Net transactions value
$0
Form type
4
Filing time
17 Mar 2023, 20:30:12 UTC
Previous filing
19 Sep 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRT Employee Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 15 Mar 2023 Common Stock 125,000 $0.5000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from March 15, 2023, with the first vesting occuring on June 15, 2023, subject to the Reporting Person's continued service through each such date.

Remarks:

Vice President, Research and Development